<DOC>
	<DOCNO>NCT03097380</DOCNO>
	<brief_summary>An open-label study use positionemissiontomography ( PET ) explore bind AZD2115 Tiotropium muscarinic receptor lung healthy volunteer inhalation .</brief_summary>
	<brief_title>PET Study Determine Muscarinic Receptor Occupancy Lungs After Inhalation AZD2115 Tiotropium</brief_title>
	<detailed_description>A phase I open-label exploratory study healthy male volunteer use positionemissiontomography ( PET ) . The study test hypothesis Tiotropium AZD2115 bind mAchRs saturable manner aim examine relationship receptor occupancy drug exposure .</detailed_description>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Provision sign date write informed consent prior study specific procedure Healthy male subject , age 20 50 year ( inclusive ) Male subject must surgically sterile use acceptable method contraception ( define barrier method conjunction spermicide ) duration study ( first dose ) 3 month last dose study drug prevent pregnancy partner Body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive weigh least 50.0 kg 100.0 kg , inclusive Able willing participate schedule evaluation abide study restriction Ability inhale study drug training device visit 1 Subjects blood donor donate blood study 3 month follow last dose study drug . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence study result subject 's ability participate study . Any clinical significant illness , medical/surgical procedure , trauma within 4 week first administration investigational medicinal product ( IMP ) Any clinically significant abnormality clinical chemistry , haematology , urinalysis result , judged investigator . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) Abnormal vital sign , 10 minute supine rest , define follow : Systolic blood pressure ( BP ) &lt; 90 mmHg &gt; 140 mmHg Diastolic BP &lt; 50 mmHg &gt; 90 mmHg Heart rate &lt; 45 bpm &gt; 100 bpm Any clinically important abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc interval change , determine investigator . This may include subject follow : PR ( PQ ) interval prolongation clinical significance judge Investigator Intermittent second third degree AV block ( AV block II Mobitz type 1 Wenchebach , asleep deep rest disqualify ) Incomplete , full , intermittent bundle branch block ( QRS le 110 m normal QRS T wave morphology acceptable evidence leave ventricular hypertrophy ) Abnormal T wave morphology , particularly protocoldefined primary lead Prolonged QT interval correct heart rate use Fridericia 's formula ( QTcF ) great 450 m shorten QTcF le 340 m family history long QT syndrome . History alcohol abuse excessive intake alcohol , judge investigator . Positive screen drug abuse visit 1 . History severe allergy/hypersensitivity ongoing clinically important allergy/hypersensitivity , seasonal allergy , judge Investigator , history hypersensitivity drug similar chemical structure class AZD2115 . Use prescribe nonprescribed medication , 4 week ( longer depend medication 's halflife ) prior administration IMP . Use drug enzyme induce property St John 's Wort within 4 week prior investigational product administration . Current smoker subject smoke used nicotine product within 6 month prior visit 1 Plasma donation within 1 month screen blood donation/blood loss equal great 500 mL 3 month prior screen . Previous enrolment present study Involvement planning and/or conduct study Participation another clinical study investigational product last 3 month Negative Allen test hand Claustrophobia would contraindicate PET measurement .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy volunteer study</keyword>
</DOC>